when will crispr stocks finally take off?

CRISPR Therapeutics' stock is unlikely to take off immediately, but it remains bullish in the long term. Here's why:

1. Market Potential and Revenue Projections:
   • The market potential for CRISPR's lead product, CASGEVY, is significant, with the treatment of 20,000 patients projected to generate $44 billion in revenue. However, the actual revenue will depend on adoption and long-term data.
   • The company's financials will improve with the split profits with Vertex, with CRISPR taking a 40% cut on CASGEVY earnings.
2. Regulatory Milestones and Market Approval:
   • The FDA approval of CASGEVY for sickle cell disease and beta-thalassemia is a major milestone, but it does not automatically lead to immediate stock price appreciation.
   • Additional approvals, such as the one for transfusion-dependent beta-thalassemia expected on March 30, 2024, could be catalysts for stock movement.
3. Volatility and Investor Sentiment:
   • The stock has been volatile, especially on news of FDA approval, with some investors selling upon the news, potentially due to the "buy the rumor, sell the news" phenomenon.
   • The stock's recent decline despite positive regulatory news suggests a need for patience and a long-term perspective.
4. Strategic Partnerships and Reimbursement:
   • The partnership with Vertex enhances CRISPR's commercialization capabilities, which could be crucial for market penetration.
   • Reimbursement agreements, like the one with the NHS for CASGEVY in England, can expand access to patients and potentially increase revenue.
5. Long-Term Financial Projections and Analyst Ratings:
   • Analysts have provided mixed earnings estimates for CRISPR, with some expecting improvements in financial performance.
   • The stock has a consensus rating of "Hold" with an average target price of $73.31, indicating a range of expectations for the stock's future performance.
6. Technological Advancements and Competitive Landscape:
   • CRISPR's position at the forefront of gene editing is a positive factor, but the market is evolving, and the company must continue to innovate to maintain its lead.
   • The success of CASGEVY and other gene therapies could pave the way for further advancements in the field, which may not immediately translate into stock price appreciation.

In conclusion, while CRISPR's long-term prospects are promising, the stock's immediate trajectory may be influenced by market dynamics and investor sentiment. The company's strategic positioning, ongoing clinical trials, and regulatory approvals will be critical in shaping its future performance.